The IHC Programme was initially planned to promote TB/HIV collaborative activities and enrolled only TB/HIV co-infected patients and their family members. In Myanmar, the scope of its intervention has since broadened to provide care and treatment to all HIV-infected patients whatever their TB status. This new programme is called IHC "PLUS". The geographic criterion to enrol has also been lifted, permitting patients from neighbouring townships to benefit from care and treatment through the programme.
Myanmar programme now serves HIV-infected patients regardless of TB status
In Myanmar, The Union's Integrated HIV Care for Tuberculosis Patients Living with HIV/AIDS (IHC) Programme has demonstrated the capacity of national tuberculosis and AIDS programmes, physicians in teaching hospitals, and primary health care facilities in townships to collaborate and provide accessible, acceptable and affordable diagnostic and treatment services for TB-HIV co-infected patients and their HIV-infected relatives.
Since its inception in 2005, the IHC has grown to cover 10 townships in Mandalay city and its environs, serving a population of 2,262,671 people and about 5,000 TB cases per year. More than 80% of adult TB patients in Mandalay and Pakokku have now received HIV tests through the programme, and about 7,515 people have received care. As of December 2010, 4,379 patients were also actively receiving antiretroviral therapy. Other advances include the renovation of the HIV outpatient rooms at Mandalay General Hospital and Mandalay Teaching Hospital taking into account infection control procedures.
The IHC programme in Myanmar currently receives funding from three donors. The Yadana Consortium, which has sponsored the programme since its inception, will continue funding through 2015. The US$ 4 million grant will provide antiretroviral therapy for 2,000 patients during the grant period.
In 2010, The 3 Diseases Fund granted the IHC Programme US$ 1 million to support the antiretroviral treatment of an additional 2,790 patients in the new IHC "PLUS" programme, which serves HIV-infected patients regardless of TB status.
In 2011, The Union became one of the sub-recipients of a Global Fund grant and will receive US$ 16 million over five years to put 12,500 HIV-infected patients on antiretroviral therapy by end of 2015.